Houghton J A, Morton C L, Adkins D A, Rahman A
Department of Molecular Pharmacology, St. Jude Children's Research Hospital, Memphis, Tennessee 38101.
Cancer Res. 1993 Sep 15;53(18):4243-50.
Prior studies from these laboratories demonstrated 3.2-fold potentiation of 5-fluorouracil (FUra) cytotoxicity by recombinant human interferon-alpha 2a (rIFN-alpha 2a) in GC3/cl colon adenocarcinoma cells that was significantly enhanced to 14-fold when FUra was combined with rIFN-alpha 2a + a mixture of the diasteroisomers of the biologically active (6S) and inactive (6R) leucovorin or 5-formyl-H4PteGlu (LV), events that were reversible by thymidine (dThd). In GC3/clTS-c3/c3 cells, deficient in thymidylate synthase, rIFN-alpha 2a cytotoxicity was not influenced by the concentration of dThd, indicating no direct effect at the level of dThd-less stress. Direct assays of thymidylate synthase indicated no significant difference between FUra-induced accumulation of total thymidylate synthase or free or unbound thymidylate synthase in cells receiving FUra + modulators. In addition, the cytotoxic activity of CB3717, a specific quinazoline-based inhibitor of thymidylate synthase, was not potentiated by rIFN-alpha 2a. These studies suggested that thymidylate synthase was not the primary target site for rIFN-alpha 2a activity. Since data indicated that a 5-fluoropyrimidine was required in the interaction among FUra, LV, and rIFN-alpha 2a, attention was focused at the level of DNA. Both DNA single-strand breaks (SSBs) and DNA double-strand breaks (DSBs) induced by FUra were significantly elevated by rIFN-alpha 2a and LV administered as single modulators and were influenced by the concentrations of both FUra and rIFN-alpha 2a. However; when FUra was combined with LV, rIFN-alpha 2a further potentiated the frequency of DNA SSBs, and data correlated with the relative cytotoxic activity of FUra-LV-rIFN-alpha 2a combinations. No effect on CB3717-induced DNA SSBs or DSBs by rIFN-alpha 2a was demonstrated. Drug exposure for 48 h was required to detect measurable differences in DNA SSB frequency among FUra-LV-rIFN-alpha 2a treatment groups and correlated with decreased clonogenic survival under these conditions. Continuous exposure to FUra (72 h) allowed shorter exposures to LV and/or rIFN-alpha 2a (48 h) to maintain maximal cytotoxicity. Shorter exposure times for FUra during continuous exposure to the modulators were less cytotoxic. Data suggest that the primary locus of the interaction among FUra, LV, and rIFN-alpha 2a lies at the level of DNA. rIFN-alpha 2a may exert its effects via enhancement of FUra base excision or incorporation into DNA, events that subsequently become influenced by thymidylate synthase inhibition and dThd-less stress and are further potentiated by LV.(ABSTRACT TRUNCATED AT 400 WORDS)
这些实验室先前的研究表明,重组人干扰素α-2a(rIFN-α2a)可使GC3/cl结肠腺癌细胞中5-氟尿嘧啶(FUra)的细胞毒性增强3.2倍,当FUra与rIFN-α2a加上生物活性(6S)和无活性(6R)亚叶酸或5-甲酰基-H4PteGlu(LV)的非对映异构体混合物联合使用时,这种增强作用显著提高到14倍,这些作用可被胸腺嘧啶核苷(dThd)逆转。在胸苷酸合成酶缺乏的GC3/clTS-c3/c3细胞中,rIFN-α2a的细胞毒性不受dThd浓度的影响,表明在dThd缺乏应激水平上没有直接作用。胸苷酸合成酶的直接测定表明,在接受FUra +调节剂的细胞中,FUra诱导的总胸苷酸合成酶或游离或未结合的胸苷酸合成酶积累之间没有显著差异。此外,rIFN-α2a并未增强CB3717(一种基于喹唑啉的胸苷酸合成酶特异性抑制剂)的细胞毒性。这些研究表明,胸苷酸合成酶不是rIFN-α2a活性的主要靶位点。由于数据表明在FUra、LV和rIFN-α2a的相互作用中需要5-氟嘧啶,因此注意力集中在DNA水平。作为单一调节剂给药的rIFN-α2a和LV可显著提高FUra诱导的DNA单链断裂(SSB)和DNA双链断裂(DSB),并且受到FUra和rIFN-α2a浓度的影响。然而,当FUra与LV联合使用时,rIFN-α2a进一步增强了DNA SSB的频率,并且数据与FUra-LV-rIFN-α2a组合的相对细胞毒性活性相关。未证明rIFN-α2a对CB3717诱导的DNA SSB或DSB有影响。需要48小时的药物暴露才能检测到FUra-LV-rIFN-α2a治疗组之间DNA SSB频率的可测量差异,并且与这些条件下克隆形成存活率的降低相关。持续暴露于FUra(72小时)允许较短时间暴露于LV和/或rIFN-α2a(48小时)以维持最大细胞毒性。在持续暴露于调节剂期间,FUra的较短暴露时间细胞毒性较小。数据表明,FUra、LV和rIFN-α2a之间相互作用的主要位点在于DNA水平。rIFN-α2a可能通过增强FUra碱基切除或掺入DNA发挥其作用,这些事件随后受到胸苷酸合成酶抑制和dThd缺乏应激的影响,并被LV进一步增强。(摘要截断于400字)